Health PEI
One Island Health System

PEI Pharmacare
P.O. Box 2000
Charlottetown, PE
C1A 7N8
www.healthpei.ca

Santé Î.-P.-É.
Un système de santé unique

Programmes provinciaux de medicaments
C.P. 2000
Charlottetown, PE
C1A 7N8
www.healthpei.ca

PEI Pharmacare Bulletin

Issue (2022 - 5) **May 9, 2022**

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (EFFECTIVE DATE: (MAY 23, 2022)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN/PDIN	MFR
Budesonide	Mylan-Budesonide AQ	64 mcg 100 mcg	Nasal Spray Nasal Spray	02241003 02230648	MYL
Criteria	Open benefit				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Drug Program, Generic Drug Program, Nursing Home Drug Program, Seniors Drug Program, Catastrophic Drug Program				

Cabotegravir	Vocabria	30 mg	Tablet	02497204	VII
Criteria	For the treatment of adult patients with HIV-1 infection who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL)				
Program Eligibility	HIV Drug Program				

Cabotegravir-rilpivirine	Cabenuva	400 mg-600 mg 600 mg-900 mg	Vial Vial	02497220 02497247	VII
Criteria	For the treatment of adult patients with HIV-1 infection who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL)				
Program Eligibility	HIV Drug Program				

Rituximab	Riabni	10 mg/ml	Vial	02513447	AMG
Criteria	For the treatment of adult patients with severe active Rheumatoid Arthritis who have failed to respond to an adequate trial with an anti-TNF agent. a) Rituximab will NOT be considered in combination with other biologic agents.				

	b) Approval for re-treatment with rituximab will only be considered for patients who have achieved a response, followed by a subsequent loss of effect and, after an interval of no less than six months from the previous dose. For the induction of remission in patients with severely active granulomatosis with polyangitis (GPA) or microscopic polyangitis (MPA) who have severe intolerance or other contraindication to cyclophosphamide, or who have failed an adequate trial of cyclophosphamide Maximum adult dose is 1000 mg by IV infusion followed two weeks later by the second 1000 mg IV infusion. For Rituximab-naive adult patients whose rituximab therapy is initiated after August 30, 2021, a rituximab biosimilar will be the product approved.
Program Eligibility	High Cost Drug Program, Catastrophic Drug Program

NOTICE

Regulations changes are expected to occur June 1, 2022, creating a Substance Use Harm Reduction Drug Program. This will replace the previous Opioid Replacement Therapy Program.

Program details will be provided via Pharmacare Bulletins and website updates in the coming weeks.